Company Overview and News

9
EU mergers and takeovers (June 20)

2h reuters
BRUSSELS, June 20 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
39IB ABFOF LGEPF DIREN BNPQY LYB HOGGF BNPQF DTEGF ICP BNPZY LGEAF PAY PWOPY GPN TOT LALWF ABRTY LGLD HRG LGEJY DTEGY LGEIY

9
EU mergers and takeovers (June 19)

21h reuters
BRUSSELS, June 19 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
39IB ABFOF DIREN BNPQY SMFG HOGGF DTEGF SMFNF LGEAF LGEIY LGEPF LYB BNPQF ICP BNPZY PAY PWOPY 8316 GPN TOT LALWF ABRTY SSUMF LGLD HRG LGEJY DTEGY

0
Telia seeks solution for Denmark

2018-06-18 thestar.com.my
The phone company executive’s patience with the Danish unit, where Telia’s fixed-line business is small and the wireless arm is “subscale,” is dwindling, Dennelind said in an interview here. He’s reviewing options in the country and wants to announce a solution – which could mean a sale of the unit – before the end of the year. (A flag flutters at the Telia telecommunication company headquarters in Helsinki, Finland, May 5, 2017.
TDCAY TDCAF CKHUF TELNF TELNY CKHUY TLTZY DTEGF DTEGY TLTZF

0
Italy's Mediaset, Cairo Communication appeal against 5G frequency auction: sources - Channel NewsAsia

2018-06-13 channelnewsasia
ROME: Italian private broadcaster Mediaset and media group Cairo Communication have filed an appeal with a regional court against rules set for an auction of frequencies for fifth-generation (5G) mobile services, a legal source and a source close to the matter said.
DTEGF DTEGY

0
UPDATE 2-EU investigates Deutsche Telekom's Dutch deal amid competition concerns

2018-06-12 reuters
BRUSSELS/STOCKHOLM (Reuters) - Deutsche Telekom faces a four-month investigation into its bid to buy the Dutch business of Swedish peer Tele2 after EU antitrust regulators voiced concerns about the deal.
CKHUF CKHUY DTEGF DTEGY

0
Big Read: France pours billions into race to dominate AI

2018-06-10 nzherald.co.nz
Tens of millions of tourists pour into Paris every year, making it the globe's most visited city - a genuine world leader.
DTEGF DTEGY

12
EU mergers and takeovers (June 8)

2018-06-08 reuters
BRUSSELS, June 8 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
CFHLF BNPQY LYB SMFG OAK BNPQF DTEGF SMFNF ICP BNPZY OAK.PRA PAY 8316 GPN LALWF SSUMF DTEGY

12
EU mergers and takeovers (June 7)

2018-06-07 reuters
BRUSSELS, June 7 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
CFHLF BNPQY LYB SMFG OAK BNPQF SMFNF DTEGF BNPZY OAK.PRA PAY 8316 GPN LALWF SSUMF DTEGY

12
EU mergers and takeovers (June 6)

2018-06-06 reuters
BRUSSELS, June 6 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
CFHLF BNPQY LYB SMFG OAK BNPQF SMFNF DTEGF BNPZY OAK.PRA PAY 8316 GPN LALWF SSUMF DTEGY

12
EU mergers and takeovers (June 5)

2018-06-05 reuters
BRUSSELS, June 5 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
CFHLF BNPQY LYB SMFG OAK BNPQF DTEGF SMFNF BNPZY OAK.PRA PAY 8316 GPN LALWF SSUMF DTEGY

8
With deal to close this week, Bayer to retire Monsanto name

2018-06-04 reuters
FRANKFURT (Reuters) - Germany’s Bayer (BAYGn.DE) will wrap up the $63 billion takeover of Monsanto (MON.N) on Thursday and also retire the U.S. seeds maker’s 117 year-old name.
506285 TMUSP 524084 MONSANTO TMUS BYRQY BAYERCROP DTEGF DTEGY

8
Bayer to retire Monsanto name after deal closure this week

2018-06-04 livemint
Frankfurt: Germany’s Bayer AG will wrap up the $63 billion acquisition of Monsanto on Thursday and also retire the US seeds maker’s 117 year-old name. The German drugmaker had received all required approvals from regulatory authorities, it said in a statement on Monday.
506285 TMUSP 524084 MONSANTO TMUS BYRQY BAYERCROP DTEGF DTEGY

8
With deal to close this week, Bayer to retire Monsanto name

2018-06-04 channelnewsasia
Germany's Bayer will wrap up the US$62.5 billion takeover of Monsanto on Thursday this week and also retire the name of the U.S. seeds maker, it said on Monday.
506285 TMUSP 524084 MONSANTO TMUS BYRQY BAYERCROP DTEGF DTEGY

0
Inmarsat To Offer Inflight Wi-Fi Services By 2019

2018-06-02 aviationweek
Inmarsat announced at the 2018 European Business Aviation Convention & Exhibition (EBACE) in Geneva that it will offer its European Aviation Network inflight Wi-Fi services to the business aviation market by January. The service integrates connectivity from a satellite, operated by Inmarsat, and an LTE-based ground network, operated by Deutsche Telekom, which covers the 28 member states of the European Union, plus Switzerland and Norway.
DTEGF DTEGY

12
EU mergers and takeovers (June 1)

2018-06-01 reuters
BRUSSELS, June 1 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
CFHLF BNPQY LYB SMFG OAK BNPQF DTEGF SMFNF BNPZY OAK.PRA PAY 8316 GPN LALWF SSUMF DTEGY

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: 251566105